LY 3074828

Drug Profile

LY 3074828

Alternative Names: Anti-IL-23 MAb; Anti-IL-23 monoclonal antibody; Anti-interleukin-23 MAb; Anti-interleukin-23 monoclonal antibody; LY-3074828

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Inflammation mediator inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis; Ulcerative colitis
  • Preclinical Crohn's disease

Most Recent Events

  • 01 Sep 2016 Phase-II clinical trials in Plaque psoriasis in USA, Germany, Japan, Puerto Rico (SC) (NCT02899988)
  • 01 Sep 2016 Preclinical trials in Crohn's disease in USA (Parenteral) before September 2016
  • 01 Sep 2016 Eli Lilly plans the phase II SERENITY trial for Crohn's disease (Treatment-experienced) in USA, United Kingdom, Australia, Austria, Canada, France, India, Japan, Netherlands, Poland, Romania, Russia, Switzerland and Ukraine (Parenteral) (NCT02891226)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top